The HIV-1 Spacer Peptide P1: A Novel Anti-retroviral Target
Funder
National Health and Medical Research Council
Funding Amount
$384,000.00
Summary
Human immunodeficiency virus type 1 (HIV-1) is the virus that causes AIDS. The treatment that is in current use, called highly active anti-retroviral therapy (HAART), has significantly delayed the onset of AIDS in HIV-1 infected patients. This therapeutic regimen requires the action of three or more drugs to generate a potency that is sufficient to suppress the virus and restrict outgrowth of resistant mutants. However, even on HAART the virus continues to replicate at a low level, and the threa ....Human immunodeficiency virus type 1 (HIV-1) is the virus that causes AIDS. The treatment that is in current use, called highly active anti-retroviral therapy (HAART), has significantly delayed the onset of AIDS in HIV-1 infected patients. This therapeutic regimen requires the action of three or more drugs to generate a potency that is sufficient to suppress the virus and restrict outgrowth of resistant mutants. However, even on HAART the virus continues to replicate at a low level, and the threat of the development of resistant mutations is ever present. Consequently, additional drug targets are required to continue the successful treatment of HIV-1 infected patients. This research is focused on a large polyprotein produced by HIV called Gag. One end of Gag contains a smaller protein called P1 that is crucial for the ability of HIV to reproduce itself. Small changes to the genetic makeup of P1 (one or two amino acids) lead to a defective virus that cannot replicate. The apparent integral role of P1 in viral replication makes it an excellent target for anti-retroviral therapy. With this project we will further our understanding of P1's role in HIV replication and look at ways we target P1 for the development of effective anti-viral agents.Read moreRead less
TSLP And Dysregulation Of Anti-viral Immunity In Atopic Dermatitis
Funder
National Health and Medical Research Council
Funding Amount
$504,097.00
Summary
Eczema (atopic dermatitis) is a frequent allergy in Australia. People with eczema can suffer very severe skin infections with some viruses, including the virus that causes cold sores, but we do not know why this happens. A newly discovered protein called TSLP is now known to be made by skin affected by eczema and there is evidence that TSLP may interfere with the way the body fights viruses. We will examine whether TSLP programs the immune system so that it is less able to fight viruses.
Study Of Papillomavirus DNA Encapsidation And Formation Of Infectious Virions
Funder
National Health and Medical Research Council
Funding Amount
$214,053.00
Summary
Papillomavirus (PV) is a sexually-transmitted virus that is a major cause of cervical cancer. Our study will determine how PV is able to form new virus particles inside infected cells. This is a critical part of the virus life-cycle, and a better understanding of this process may allow it to be trageted by anti-viral treatments. In addition, we will develop a method to create non-harmful virus particles which we will use to study human immune responses to the virus.
The diversity of HIV quasispecies within a single AIDS patient is far greater than the global diversity of influeneza annually, highlighting the enormous burden HIV imposes on the immune network. The capacity of HIV-1 to evolve quickly has significantly impaired our effort to produce effective vaccine and long lasting treatment strategy. This project utilizes multidisciplinary approaches to delineate determinants that drives the diversification of HIV-1.